vs
博士伦（BLCO）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Rivian Automotive, Inc.的1.1倍（$1.4B vs $1.3B），博士伦净利率更高（-4.1% vs -63.1%，领先58.9%），博士伦同比增速更快（9.8% vs -25.8%），博士伦自由现金流更多（$60.0M vs $-1.1B），过去两年博士伦的营收复合增速更高（13.1% vs 3.3%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
BLCO vs RIVN — 直观对比
营收规模更大
BLCO
是对方的1.1倍
$1.3B
营收增速更快
BLCO
高出35.6%
-25.8%
净利率更高
BLCO
高出58.9%
-63.1%
自由现金流更多
BLCO
多$1.2B
$-1.1B
两年增速更快
BLCO
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.3B |
| 净利润 | $-58.0M | $-811.0M |
| 毛利率 | — | 9.3% |
| 营业利润率 | 8.0% | -64.8% |
| 净利率 | -4.1% | -63.1% |
| 营收同比 | 9.8% | -25.8% |
| 净利润同比 | -1833.3% | -9.0% |
| 每股收益（稀释后） | $-0.16 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORIVN
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.2B | $874.0M | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
净利润BLCORIVN
| Q4 25 | $-58.0M | $-811.0M | ||
| Q3 25 | $-28.0M | $-1.2B | ||
| Q2 25 | $-62.0M | $-1.1B | ||
| Q1 25 | $-212.0M | $-545.0M | ||
| Q4 24 | $-3.0M | $-744.0M | ||
| Q3 24 | $4.0M | $-1.1B | ||
| Q2 24 | $-151.0M | $-1.5B | ||
| Q1 24 | $-167.0M | $-1.4B |
毛利率BLCORIVN
| Q4 25 | — | 9.3% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | -15.8% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | -44.9% | ||
| Q2 24 | — | -38.9% | ||
| Q1 24 | — | -43.8% |
营业利润率BLCORIVN
| Q4 25 | 8.0% | -64.8% | ||
| Q3 25 | 7.4% | -63.1% | ||
| Q2 25 | -0.9% | -85.5% | ||
| Q1 25 | -7.3% | -52.8% | ||
| Q4 24 | 6.8% | -38.1% | ||
| Q3 24 | 3.6% | -133.8% | ||
| Q2 24 | 2.1% | -118.7% | ||
| Q1 24 | 0.5% | -123.3% |
净利率BLCORIVN
| Q4 25 | -4.1% | -63.1% | ||
| Q3 25 | -2.2% | -75.3% | ||
| Q2 25 | -4.9% | -85.7% | ||
| Q1 25 | -18.6% | -44.0% | ||
| Q4 24 | -0.2% | -42.9% | ||
| Q3 24 | 0.3% | -125.9% | ||
| Q2 24 | -12.4% | -125.8% | ||
| Q1 24 | -15.2% | -120.1% |
每股收益（稀释后）BLCORIVN
| Q4 25 | $-0.16 | $-0.66 | ||
| Q3 25 | $-0.08 | $-0.96 | ||
| Q2 25 | $-0.18 | $-0.97 | ||
| Q1 25 | $-0.60 | $-0.48 | ||
| Q4 24 | $-0.00 | $-0.67 | ||
| Q3 24 | $0.01 | $-1.08 | ||
| Q2 24 | $-0.43 | $-1.46 | ||
| Q1 24 | $-0.48 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $6.1B |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $4.6B |
| 总资产 | $14.0B | $14.9B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCORIVN
| Q4 25 | $383.0M | $6.1B | ||
| Q3 25 | $310.0M | $7.1B | ||
| Q2 25 | $266.0M | $7.5B | ||
| Q1 25 | $202.0M | $7.2B | ||
| Q4 24 | $305.0M | $7.7B | ||
| Q3 24 | $329.0M | $6.7B | ||
| Q2 24 | $285.0M | $7.9B | ||
| Q1 24 | $315.0M | $7.9B |
总债务BLCORIVN
| Q4 25 | $5.0B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | $5.5B | ||
| Q1 24 | $4.6B | $4.4B |
股东权益BLCORIVN
| Q4 25 | $6.4B | $4.6B | ||
| Q3 25 | $6.4B | $5.1B | ||
| Q2 25 | $6.4B | $6.1B | ||
| Q1 25 | $6.4B | $6.2B | ||
| Q4 24 | $6.5B | $6.6B | ||
| Q3 24 | $6.6B | $5.9B | ||
| Q2 24 | $6.5B | $6.8B | ||
| Q1 24 | $6.7B | $8.1B |
总资产BLCORIVN
| Q4 25 | $14.0B | $14.9B | ||
| Q3 25 | $13.8B | $15.2B | ||
| Q2 25 | $13.8B | $15.6B | ||
| Q1 25 | $13.4B | $15.5B | ||
| Q4 24 | $13.5B | $15.4B | ||
| Q3 24 | $13.5B | $14.3B | ||
| Q2 24 | $13.3B | $15.4B | ||
| Q1 24 | $13.3B | $15.7B |
负债/权益比BLCORIVN
| Q4 25 | 0.78× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | 0.81× | ||
| Q1 24 | 0.69× | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $-1.1B |
| 自由现金流率自由现金流/营收 | 4.3% | -89.0% |
| 资本支出强度资本支出/营收 | 5.4% | 36.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $-2.5B |
8季度趋势，按日历期对齐
经营现金流BLCORIVN
| Q4 25 | $136.0M | $-681.0M | ||
| Q3 25 | $137.0M | $26.0M | ||
| Q2 25 | $35.0M | $64.0M | ||
| Q1 25 | $-25.0M | $-188.0M | ||
| Q4 24 | $22.0M | $1.2B | ||
| Q3 24 | $154.0M | $-876.0M | ||
| Q2 24 | $15.0M | $-754.0M | ||
| Q1 24 | $41.0M | $-1.3B |
自由现金流BLCORIVN
| Q4 25 | $60.0M | $-1.1B | ||
| Q3 25 | $63.0M | $-421.0M | ||
| Q2 25 | $-54.0M | $-398.0M | ||
| Q1 25 | $-135.0M | $-526.0M | ||
| Q4 24 | $-70.0M | $856.0M | ||
| Q3 24 | $94.0M | $-1.2B | ||
| Q2 24 | $-57.0M | $-1.0B | ||
| Q1 24 | $-26.0M | $-1.5B |
自由现金流率BLCORIVN
| Q4 25 | 4.3% | -89.0% | ||
| Q3 25 | 4.9% | -27.0% | ||
| Q2 25 | -4.2% | -30.5% | ||
| Q1 25 | -11.9% | -42.4% | ||
| Q4 24 | -5.5% | 49.4% | ||
| Q3 24 | 7.9% | -131.9% | ||
| Q2 24 | -4.7% | -89.6% | ||
| Q1 24 | -2.4% | -126.5% |
资本支出强度BLCORIVN
| Q4 25 | 5.4% | 36.0% | ||
| Q3 25 | 5.8% | 28.7% | ||
| Q2 25 | 7.0% | 35.5% | ||
| Q1 25 | 9.7% | 27.3% | ||
| Q4 24 | 7.2% | 18.9% | ||
| Q3 24 | 5.0% | 31.7% | ||
| Q2 24 | 5.9% | 24.4% | ||
| Q1 24 | 6.1% | 21.1% |
现金转化率BLCORIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
